HomeBiosimilar Antibodies

Biosimilar Antibodies

Cat.No. Product Name Information Isotype
A2354 Anti-SLAMF6 / CD352 Anti-SLAMF6 / CD352 is a humanized monoclonal antibody (EC-mAb) targeting CD352 (SLAM family member 6; SLAM6) with potential antineoplastic activity. MW : 145.5 KD Human IgG1
A2355 Anti-SIRPg Anti-SIRPg is a recombinant human antibody that acts against anti-SIRPG (anti-Signal-Regulatory Protein Gamma). MW: 145.5 KD Human IgG4SP
A2356 Refanezumab (Anti-Siglec-4a / MAG) Refanezumab (Anti-Siglec-4a / MAG) is an IgG1-type humanised monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. MW: 145.5 KD Human IgG1
A2357 Vadastuximab (Anti-Siglec-3 / CD33) Vadastuximab (Anti-Siglec-3 / CD33) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine. MW : 150 KD. Human IgG1
A2358 Inotuzumab (Anti-Siglec-2 / CD22) Inotuzumab (Anti-Siglec-2 / CD22) is a humanized IgG4, κ monoclonal antibody that targets CD22. Inotuzumab can be used for the research of acute lymphoblastic leukaemia and non-Hodgkin lymphoma. MW : 144.78 kD. Human IgG1
A2359 Anti-Sialyl-Lewis A Anti-Sialyl-Lewis A is a human monoclonal antibody against the carbohydrate antigen sialyl-Lewis A (carbohydrate antigen 19-9; CA19-9) with potential antineoplastic activity. MW: 145.5 kD. Human IgG1
A2360 Dezamizumab (Anti-Serum Amyloid P / SAP) Dezamizumab (Anti-Serum Amyloid P / SAP) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody with potential anti-amyloid activity. MW: 144.18 kD. Human IgG1
A2361 Pepinemab (Anti-SEMA4D / CD100) Pepinemab (Anti-SEMA4D / CD100) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), which is a regulator of neuronal development and plays a role in a variety of cellular processes. MW : 145.5 kD. Human IgG4SP
A3176 Human IgG2sa isotype control Human IgG2sa isotype control is suitable for use as a non-targeting isotype control in various in vitro and in vivo studies, is the isotype control of human IgG2sa antibody. Human IgG2SA-Kappa
A2363 Anti-RTN4 / NOGO Anti-RTN4 / NOGO is an antibody acting against anti-RTN4. MW: 145.4 kD. Human IgG1
A2364 Palivizumab (Anti-RSV-F) Palivizumab (Anti-RSV-F) is a humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. MW : 145.5 kD. Human IgG1
A2365 Rosmantuzumab (anti-RSPO3) Rosmantuzumab (OMP-131R10) is an immunoglobulin (Ig) G1 humanised monoclonal antibody targeting human R-spondin 3 (RSPO3) with potential immunostimulating and antineoplastic activities. MW: 145.5 kD. Human IgG1
A2367 Anti-ROBO1 Anti-ROBO1 is a bispecific antigen-binding construct targeting ROBO1, with a single-chain variable region antibody fragment ScFV binding to the surface antigen of immune cells and a Slit2D2 protein fragment binding to the surface antigen Robo1 of tumour cells. MW: 145.5 kD. Human IgG1
A2368 Roledumab (Anti-RHD / CD240d) Roledumab (Anti-RHD / CD240d) is a human recombinant monoclonal anti-RhD antibody with the potential to prevent RhD allo-immunization. MW: 145.5 kD. Human IgG1
A2369 Anti-RGMC / HFE2 Anti-RGMC / HFE2 is a humanized monoclonal antibody directed against the bone morphogenetic proteins (BMPs) co-receptor hemojuvelin (HJV) with potential to treat anemia of inflammation and other forms of anemia. MW: 145.5 kD. Human IgG1